Åsa Petersén
Titel
forskare
Organisation
046-2221686
+46709422930
Asa [dot] Petersen [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2013
- 2012
- Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
- Expression of Mutant Huntingtin in Leptin Receptor-Expressing Neurons Does Not Control the Metabolic and Psychiatric Phenotype of the BACHD Mouse.
- For Better or for Worse: Lifeworld, System and Family Caregiving for a Chronic Genetic Disease.
- Progranulin Bridges Energy Homeostasis and Fronto-Temporal Dementia
- 2011
- 2010
- A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons
- Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses.
- Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.
- Hypothalamic and Neuroendocrine Changes in Huntington's Disease.
- NEUROPEPTIDE AND HYPOTHALAMUS CHANGES IN FRONTOTEMPORAL DEMENTIA AND HUNTINGTON'S DISEASE
- Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
- 2009
- Huntington's Disease - New Perspectives Based on Neuroendocrine Changes in Rodent Models.
- Increased levels of cocaine and amphetamine regulated transcript in two animal models of depression and anxiety.
- Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model
- Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt.
- Malignt neuroleptikasyndrom--sällsynt diagnos med hög dödlighet.
- Nortriptyline mediates behavioral effects without affecting hippocampal cytogenesis in a genetic rat depression model.
- Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin.
- Reduced CSF CART in dementia with Lewy bodies.
- 2008
- Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus
- Cocaine and amphetamine regulated transcript (CART) in suicide attempters.
- Escitalopram reduces increased hippocampal cytogenesis in a genetic rat depression model.
- Hippocampal cytogenesis is increased in FSL strain, a genetic rat model of depression. Escitalopram reduces increased cell number
- Hippocampal cytogenesis is increased in a genetic rat model of depression. Escitalopram reduces increased cell number
- Increased metabolism in the R6/2 mouse model of Huntington's disease.
- Islet beta-cell area and hormone expression are unaltered in Huntington's disease.
- Role of neuroticism and neurochemical changes in suicidal behaviour
- Sex differences in a transgenic rat model of Huntington's disease: decreased 17 beta-estradiol levels correlate with reduced numbers of DARPP32(+) neurons in males
- Transthyretin in cerebrospinal fluid from suicide attempters.
- 2007
- Cocaine- and amphetamine-regulated transcript is increased in Huntington disease.
- Orexin and psychiatric symptoms in suicide attempters.
- Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates
- Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.
- Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.
- Testicular degeneration in Huntington disease
- Transthyretin in cerebral fluid from suicide attempters
- 2006
- Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.
- Hypothalamic-endocrine aspects in Huntington's disease.
- Laminin {alpha}1 chain improves laminin {alpha}2 chain deficient peripheral neuropathy.
- Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat
- Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
- 2005
- Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient.
- Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
- Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice
- Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
- Orexin loss in Huntington's disease.
- Proteolysis of NR2B by calpain in the hippocampus of epileptic rats.
- Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.
- Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
- The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
- 2004
- 2002
- Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice.
- Huntington's disease: the mystery unfolds?
- Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
- 2001
- Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death
- Effects of dopamine and excitotoxicity in experimental models of Huntington's disease
- Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration
- Huntingtons sjukdom - ännu ett galet protein?
- Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine
- Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors
- 2000
- 1999
